Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis

References

• Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60(7):2193–200.
   PubMed Web of Science ®Google Scholar
• Nakashima R, Imura Y, Kobayashi S, Yukawa N, Yoshifuji H, Nojima T, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology. 2010;49(3):433–40.
   PubMed Web of Science ®Google Scholar
• Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology. 2010;49(9):1713–9.
   PubMed Web of Science ®Google Scholar
• Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res. 2012;64(10):1602–10.
   Web of Science ®Google Scholar
• Muro Y, Sugiura K, Hoshino K, Akiyama M, Tamakoshi K. Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Res Ther. 2011;13(6):R214.
   PubMed Web of Science ®Google Scholar
• Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri S, Iwamoto N, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology. 2012;51(7):1278–84.
   PubMed Web of Science ®Google Scholar
• Gono T, Kawaguchi Y, Ozeki E, Ota Y, Satoh T, Kuwana M, et al. Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Mod Rheumatol. 2011;21(2):223–7.
   PubMed Web of Science ®Google Scholar
• Takada T, Aoki A, Asakawa K, Sakagami T, Moriyama H, Narita I, et al. Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis. Respir Med. 2015;109(9):1174–80.
   PubMed Web of Science ®Google Scholar
• Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology. 2012;51(9):1563–70.
   PubMed Web of Science ®Google Scholar
• Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford). 2014;53(12):2196–203.
   PubMed Web of Science ®Google Scholar
• Kawasumi H, Gono T, Kawaguchi Y, Kaneko H, Katsumata Y, Hanaoka M, et al. IL-6, IL-8, and IL-10 are associated with hyperferritinemia in rapidly progressive interstitial lung disease with polymyositis/dermatomyositis. Bio Med Res Int. 2014;2014:815245.
   Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344–7.
   PubMed Web of Science ®Google Scholar
• Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis siné myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002;46(4):626–36.
   PubMed Web of Science ®Google Scholar
• Gono T, Okazaki Y, Murakami A, Kuwana M. Improved quantification of a commercial enzyme-linked immunosorbent assay kit for measuring anti-MDA5 antibody. Mod Rheumatol. 2018; Epub doi 10.1080/14397595.2018.1452179.
   Web of Science ®Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.
   PubMed Web of Science ®Google Scholar
• Kotani T, Takeuchi T, Makino S, Hata K, Yoshida S, Nagai K, et al. Combination with corticosteroids and cyclosporin: A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol. 2011;30(8):1021–8.
   PubMed Web of Science ®Google Scholar
• Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005;32:1719–26.
   PubMed Web of Science ®Google Scholar
• Sato S, Kuwana M, Fujita T, Suzuki Y. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol. 2013;23(3):496–502.
   PubMed Web of Science ®Google Scholar
• Sato S, Murakami A, Kuwajima A, Takehara K, Mimori T, Kawakami A, et al. Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. PLoS One. 2016;11(4):e0154285.
   PubMed Web of Science ®Google Scholar
• Abe Y, Matsushita M, Tada K, Yamaji K, Takasaki Y, Tamura N. Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody-positive inflammatory myositis. Rheumatology (Oxford). 2017;56(9):1492–7.
   PubMed Web of Science ®Google Scholar
• Matsushita T, Mizumaki K, Kano M, Yagi N, Tennichi M, Takeuchi A, et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol. 2017;176(2):395–402.
   PubMed Web of Science ®Google Scholar
• Enomoto Y, Suzuki Y, Hozumi H, Mori K, Kono M, Karayama M, et al. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease. Arthritis Res Ther. 2017;19(1):9
   PubMedGoogle Scholar
• Mildvan D, Spritzler J, Grossberg SE, Fahey JL, Johnston DM, Schock BR, et al. Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection. Clin Infect Dis. 2005;40(6):853–8.
   PubMed Web of Science ®Google Scholar
• Cesur S, Aslan T, Hoca NT, Cimen F, Tarhan G, Cifci A, et al. Clinical importance of serum neopterin level in patients with pulmonary tuberculosis. Int J Mycobacteriol. 2014;3(1):5–8.
   PubMedGoogle Scholar
• Sucher R, Schroecksnadel K, Weiss G, Margreiter R, Fuchs D, Brandacher G. Neopterin, a prognostic marker in human malignancies. Cancer Lett. 2010;287(1):13–22.
   PubMed Web of Science ®Google Scholar
• Mahmoud RA, El-Gendi HI, Ahmed HH. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus. Clin Biochem. 2005;38(2):134–41.
   PubMed Web of Science ®Google Scholar
• Nassonov EL, Samsonov MY, Tilz GP, Beketova TV, Semenkova EN, Baranov A, et al. Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis. J Rheumatol. 1997;24:666–70.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, De Amici M, Aramini L, Ruperto N, Martini A. Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis. Arch Dis Child. 1993;69(2):232–5.
   PubMed Web of Science ®Google Scholar
• Samsonov MY, Nassonov EL, Tilz GP, Geht BM, Demel U, Gurkina GT, et al. Elevated serum levels of neopterin in adult patients with polymyositis/dermatomyositis. Br J Rheumatol. 1997;36(6):656–60.
   PubMedGoogle Scholar
• Saito M, Chihara J, Mouri T, Kurachi D, Yamamoto T, Nakajima S. Elevated local production of neopterin from alveolar macrophages in patients with internal lung diseases. Gen Pharmacol. 1996;27(3):483–6.
   PubMedGoogle Scholar
• Colafrancesco S, Priori R, Alessandri C, Perricone C, Pendolino M, Picarelli G, et al. IL-18 serum level in adult onset Still’s disease: a marker of disease activity. Int J Inflam. 2012;2012:156890.
   PubMedGoogle Scholar
• Andert SE, Griesmacher A, Zuckermann A, Muller MM. Neopterin release from human endothelial cells is triggered by interferon-gamma. Clin Exp Immunol. 1992;88(3):555–8.
   PubMed Web of Science ®Google Scholar